Mefloquine identified as promising potential drug to combat COVID-19

Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.

Covid-19 Drug Mefloquine

In a breakthrough study, researchers from Tokyo University of Science and collaborating institutions in Japan have identified the antimalarial drug mefloquine as a potential drug that could be used to effectively treat patients with COVID-19.

Lead scientist in the team, Dr Koichi Watashi, stated: “To identify drugs with higher antiviral potency than existing antivirals, we first screened approved antiparasitic/antiprotozoal drugs. We found that mefloquine had the highest anti-SARS-CoV-2 activity among the tested compounds… In our cell assays, mefloquine readily reduced the viral RNA levels when applied at the viral entry phase but showed no activity during virus-cell attachment. This shows that mefloquine is effective on SARS-CoV-2 entry into cells after attachment on cell surface.”

To bolster mefloquine’s antiviral activity, the team looked into the possibility of combining mefloquine with nelfinavir which inhibits the replication step of SARS-CoV-2. They observed that the two drugs acted in “synergy” and that the drug combination demonstrated greater antiviral activity than when they were used alone, without being toxic to the cells in the cell lines.

The researchers also mathematically modelled the effectiveness of mefloquine to predict its potential real-world impact if applied to treat COVID-19. They predicted that mefloquine could reduce the overall viral load in affected patients to under seven percent and shorten the ‘time-till-virus-elimination’ by 6.1 days.

The team say the next stage of the study will be to go to clinical trials. Due to the severity of the pandemic, some approved drugs, such as hydroxychloroquine, lopinavir and interferon, have already been put to clinical use against SARS-CoV-2, however their clinical efficacies are not yet well-established. Only remdesivir has been approved for clinical use against severe COVID-19, although its efficacy is still being debated. The researchers emphasise that mefloquine is therefore an exciting potential drug to effectively treat COVID-19 patients.

The study was published in Frontiers in Microbiology.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.